In Advanced Myxoid Liposarcoma, Is Trabectedin Winning?

Published Date: 05 Feb 2024

Noninferiority against more toxic chemotherapy is supported by statistics, although the findings are far from conclusive.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study finds that AI is better at forecasting the risk of developing cancer.

2.

When it comes to LBCL relapse in complete remission, ASCT outperforms CAR T-cell therapy.

3.

In leukemia, allogeneic HCT is beneficial following primary induction failure.

4.

ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer

5.

Major Shifts in Urothelial Cancer Care: Immunotherapy Redefines Standards


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot